New Rhein is a global venture capital fund with a private equity approach to investing. We take significant ownership positions in pharma and medical device companies with clinical-stage assets.
UNMET MEDICAL NEED
We target companies that develop novel solutions to address large, underserved needs in healthcare and can be used within current treatment paradigms.
PROVEN SCIENTIFIC CONCEPT
Companies that have assets with at least initial safety and efficacy data in humans. 505(b)(2) products are of high interest, as well as products with strong clinical proof of concept data.
CLINICAL & REGULATORY PLAN
Companies should have a clearly defined path to approval, validated by regulatory bodies, and supported by a feasible and practical execution plan.
IP/ MARKET EXCLUSIVITY
Products should be clearly differentiated in one or more of the following ways: safer, more effective, more compliantly used by patients, and lower cost. Orphan designations are of high interest.
HEALTH ECONOMIC VALUE
We believe that "Innovation drives greater risk-adjusted return than Invention". Treatments today must improve access and reduce costs. One way to do so is to innovate upon existing science and existing products, rather than inventing new approaches.